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Abstract
Background: Leptin, a 16 kDa polypeptide hormone, implicated in various physiological processes, exerts its
action through the leptin receptor, a member of the class I cytokine receptor family. Both leptin and leptin
receptor have recently been implicated in processes leading to breast cancer initiation and progression in animal
models and humans. An A to G transition mutation in codon 223 in exon 6 of the leptin receptor gene, resulting
in glutamine to arginine substitution (Gln223Arg), lies within the first of two putative leptin-binding regions and
may be associated with impaired signaling capacity of the leptin receptor. This study was designed to assess the
role of this polymorphism in breast cancer susceptibility in Nigerian women.
Methods: We utilized a polymerase chain reaction (PCR)-based restriction fragment length polymorphism
(RFLP) assay to evaluate the association between the Gln223Arg polymorphism of the leptin receptor gene and
breast risk in Nigeria in a case control study involving 209 women with breast cancer and 209 controls without
the disease. Study participants were recruited from surgical outpatient clinics and surgical wards of four University
Teaching Hospitals located in Midwestern and southeastern Nigeria between September 2002 and April 2004.
Results: Premenopausal women carrying at least one LEPR 223Arg allele were at a modestly increased risk of
breast cancer after adjusting for confounders (OR = 1.8, 95% confidence interval [CI] 1.0–3.2, p = 0.07). There
was no association with postmenopausal breast cancer risk (OR = 0.9, 95% CI 0.4–1.8, p = 0.68).
Conclusion: Our results suggest that the LEPR Gln223Arg polymorphism in the extracellular domain of the LEPR
receptor gene is associated with a modestly increased risk of premenopausal breast cancer in Nigerian women.
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Background
Leptin, a 16 kDa polypeptide hormone produced pre-
dominantly by white adipose tissue [1], plays an impor-
tant role in body weight homeostasis through effects on
food intake and energy expenditure [2,3]. In addition to
the regulation of body weight, leptin also influences
hematopoiesis, reproduction, angiogenesis, and immune
processes [4-6]. Leptin exerts its physiological action
through the leptin receptor (LEPR), a member of the class
I cytokine receptor family. The leptin receptor is a single
transmembrane protein and has several alternatively
spliced isoforms (one long isoform and several short iso-
forms) that are distributed in many tissues [7,8]. LEPRs
have been detected in human breast epithelial cell lines,
breast cancer-derived cell lines (T47-D and MCF-7) and in
human breast cancer tissue specimens [9-11]. In addition,
leptin consistently stimulates the proliferation of benign
and malignant epithelial breast cells in vitro as measured
by DNA synthesis, cellular density and up-regulation of
downstream regulators of cellular proliferation [9-12].
Several single nucleotide polymorphisms (SNPs) in the
LEPR gene have been described. Chung et al. [13] identi-
fied three allelic variants associated with amino acid
changes (Lys109Arg, Gln223Arg, and Lys656Asn), three
silent mutations (nt 1222 T→C, nt 3217 A→G, and nt
3250 G→A), and four intronic sequence variants. All three
amino acids (Lys109Arg, Gln223Arg, and Lys656Asn) are
conserved among rat, mouse, and human species [14,15],
but only Gln223Arg and Lys656Asn result in changes in
charge (neutral to positive and positive to neutral, respec-
tively) and are, therefore, most likely to have functional
consequences. The Gln223Arg polymorphism is within
the region encoding the extracellular domain of the leptin
receptor and therefore, the amino acid change affects all
forms of the receptor. It has been shown that the LEPR
Gln223Arg polymorphism is associated with variation in
ligand binding; higher levels of ligand binding activity has
been demonstrated in individuals homozygous for the G
(LEPR Arg223Arg) allele than for carriers of the A (LEPR
223Gln) allele [16].
Despite these premises, very few studies have considered
the role of serum leptin levels and polymorphisms in lep-
tin and LEPR genes in breast cancer risk [17-23]. Four
studies [17-20] on plasma leptin levels and breast cancer
risk have shown conflicting results; one in the Italian pop-
ulation [17] and another among the Chinese [18]
reported significant increased risk of breast cancer with
higher serum leptin levels while two other studies [19,20]
in the Greek and U.S. populations, respectively, found no
associations. Of two studies that evaluated relationship
between LEPR Gln223Arg polymorphism and serum lep-
tin levels, one study among college students in Greece
[21] reported significantly higher leptin levels in heterozy-
gote (LEPR  Gln223Arg) and homozygote (LEPR
Arg223Arg) carriers of the G allele; the second study by
Quinton et al. [16] among postmenopausal British
women reported lower leptin levels among carriers of the
G allele. Only two studies [22,23] have examined allelic
variants of the LEPR genes in breast cancer susceptibility;
one [22] reported positive association among Tunisian
women while the other [23] found no association
between these variants and breast cancer risk in Korean
women. We are unaware of any study of this susceptibility
marker and breast cancer risk in black populations.
Although, several polymorphisms have been described in
the LEPR gene, we have chosen in this exploratory study
to evaluate the role of the LEPR  Gln223Arg polymor-
phism in breast cancer susceptibility in Nigerian women
since it is the most studied functional LEPR gene polymor-
phism in human subjects.
Methods
Subjects
The recruitment of participants for this study from four
University Teaching Hospitals located in southern Nigeria
(University of Benin Teaching Hospital, Benin City;
Nnamdi Azikiwe University Teaching Hospital, Nnewi;
University of Nigeria Teaching Hospital, Enugu; and Uni-
versity of Port Harcourt Teaching Hospital, Port Harcourt
between September 2002 and April 2004) has been
described elsewhere [24,25]. Briefly, 209 women with
confirmed breast cancer and 209 age-matched control
subjects without the disease or any other malignancy were
recruited during surgical outpatient visits or hospital
admissions. Control subjects were being treated in the
same hospitals for non-malignant diseases including
unintentional injuries, acute inflammatory diseases such
as chronic duodenal ulcer, appendicitis, pelvic inflamma-
tory disease and urolithiasis. The study protocol was
approved by the Institutional Review Board of University
of Pittsburgh and the Ethics and Research Committees of
the Nigerian institutions prior to commencement.
Women with suspected breast cancer without histological
confirmation and those that refused sample donation
were excluded from the study.
Study participants signed informed consent after detailed
explanation of the purpose, risks and benefits, confidenti-
ality and rights of participants prior to recruitment. Data
in respect of reproductive history, demographic character-
istics, occupational exposure to pesticides and fertilizers
and lifestyle choices including alcohol consumption and
cigarette smoking were obtained using interviewer-
administered questionnaires. Anthropometric measure-
ments including height, weight, waist and hip circumfer-
ences were taken at the end of the interview.
Sample Donation and Preparation
Ten milliliters (ml) blood sample was collected into one
10 ml K3-EDTA vacutainer tube from each of the studyBMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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participants at the end of the interview. The buffy coat was
prepared by centrifuging whole blood 2500 × g for 10 min
at room temperature. All the samples were stored at -20°C
in the Nigerian coordinating center at the University of
Benin Teaching Hospital and later shipped to University
of Pittsburgh in dry ice. Samples were stored at -80°C at
the University of Pittsburgh until DNA extraction. DNA
extraction from buffy coats (and clots for subjects with no
buffy coats) was carried out using QIAamp DNA Mini Kits
(for buffy coats) and QIAamp DNA Midi Kits (for blood
clots) protocols (QIAGEN Inc, Valencia, CA). The
extracted DNA was stored at 4°C until used for polymer-
ase chain reaction (PCR) and restriction fragment length
(RFLP) analysis.
PCR and RFLP analysis
Genomic DNA from the cases and control subjects were
analyzed for the presence of the A to G mutation at codon
223 of the LEPR gene by a PCR-based restriction fragment
length polymorphism (RFLP) assay. PCR amplification of
an 80 bp fragment of the LEPR gene, including part of
exon 6 that contains the polymorphism was carried out
using forward primer: AAACTCAACGACACTCTCCTT and
reverse primer: TGAACTGACATTAGAGGTGAC. A 50 μl
PCR reaction mixture containing 2 μl of genomic DNA, 5
μl of deoxynucleotide triphosphates, 3 μl each of forward
and reverse primers, 5 μl of 10× buffer, 1.5 μl of MgCl2
and 0.5 μl of Taq polymerase was placed in a thermocy-
cler. After denaturing for 5 min at 95°C, the DNA was
amplified for 35 cycles at 95°C for 30 sec, 59°C for 45 sec,
and 72°C for 60 sec, followed by a 5 min extension at
72°C. A positive control containing genomic DNA and a
negative control containing everything except DNA were
included in the PCR experiment. Five μl of each PCR prod-
uct, including the controls, were verified on a 3% agarose
gel to ensure that the expected 80 bp product was gener-
ated.
Restriction digest for the DNA fragment was carried out
using Msp 1 restriction enzyme. Fifteen μl of the PCR
product was digested for 16 h overnight at 37°C with 10
units of Msp 1 (New England Biolabs). The product of the
restriction digest was mixed with 10 μl of loading dye and
verified on a 3% agarose gel (with Ethidium bromide)
electrophoresis in a 1× Tris-Borate-EDTA buffer at 200 V
for 60 min. The presence of an A at position 668 (LEPR
codon 223) generated a unique 80 bp fragment, while the
80 bp fragment was divided into unique 58 bp and 22 bp
fragments when position 668 contains a G. The gels were
visualized by UV light and the RFLP gel electrophoresis
products were read by two independent persons who were
unaware of the identities of samples as either cases or con-
trols. DNA extraction and RFLP assays employing Msp 1
restriction enzyme were successful in 209 cases and 209
control subjects; therefore the analysis is restricted to this
sample of women.
Statistical Analyses
Statistical analysis was carried out using the Statistical
Analysis System (SAS) software (Version 8.0). Although
the original data was matched by age, the analysis of the
genetic data was conducted on the unmatched sample,
since DNA was not available on all the study participants.
Therefore an unmatched analysis was conducted and an
adjustment for age was performed. Unconditional logistic
regression was used to assess the association between the
LEPR Gln223Arg genotypes and breast cancer risk in the
whole sample. Stratified analyses according to menopau-
sal status were then carried out. Relevant risk factors that
were identified as significant predictors of breast cancer
risk were controlled for in the multivariate logistic regres-
sion models.
Results
Demographic Characteristics
A total of 418 female participants were recruited from the
surgical outpatient clinics and surgical wards of the four
University Teaching Hospitals in southern Nigeria. Two
hundred and nine of them were being managed for vari-
ous stages of breast cancer while the remaining 209
women, being treated for various non-malignant diseases
in the same institutions served as control subjects. The
ages of the cases and control subjects were similar with
mean ages of 46.1 ± 12.63 years and 47.1 ± 13.50 years for
cases and controls, respectively. Details on the associa-
tions between anthropometric, demographic and repro-
ductive variables are reported elsewhere [26,27].
Allele and Genotype Frequencies in All women
Our results indicate that the LEPR Gln223Arg variant is
highly polymorphic in the Nigerian population. The dis-
tribution of the LEPR Gln223Arg alleles and genotypes are
shown in Table 1. When all study participants were con-
sidered together, the distribution of the LEPR  223Gln
allele was similar in cases and controls with allele frequen-
cies of 0.49 and 0.51, respectively while the frequency of
the LEPR 223Arg allele was 0.51 and 0.49, respectively.
The homozygous LEPR Gln223Gln genotype was slightly
less common in the cases compared to the controls with
genotype frequencies of 0.22 and 0.27, respectively while
the heterozygous LEPR Gln223Arg genotype was equally
distributed among cases and controls with frequency of
0.51 in both cases and control subjects. The homozygous
Arg223Arg genotype was slightly more common in the
cases compared to the controls with frequencies of 0.27
and 0.22, respectively. The distribution of the LEPR
223Gln and 223Arg alleles among the controls were in
Hardy-Weinberg equilibrium overall and in both premen-
opausal and postmenopausal women.BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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Premenopausal Women
The DNA extraction and RFLP Msp 1 assays were success-
ful in 114 premenopausal breast cancer cases and 121
control subjects. The LEPR 223Gln allele was less frequent
in premenopausal breast cancer cases compared to those
without breast cancer with allele frequencies of 0.46 and
0.54, respectively. The wild-type LEPR Gln223Gln geno-
type was less frequent in the women with breast cancer
compared to those without the disease, with genotype fre-
quencies of 0.20 and 0.31, respectively. (Table 1).
Postmenopausal Women
There was no apparent difference in the distribution of the
LEPR 223Gln and LEPR 223Arg alleles in postmenopausal
women with breast cancer compared to the control sub-
jects. The LEPR  Gln223Gln genotype frequencies were
0.24 in cases and 0.21 in the controls as shown in Table 1.
LEPR Gln223Arg Genotypes and Breast Cancer Risk in All 
Women
Compared to women with the LEPR Gln223Gln geno-
type, those harboring the heterozygous LEPR Gln223Arg
genotype (OR = 1.2, 95% CI 0.8–2.0, p = 0.42) and the
homozygous mutant LEPR  Arg223Arg genotype (OR =
1.5, 95% CI 0.8–2.6, p = 0.16) had no significant
increased risk of breast cancer.
The presence of at least one LEPR 223Arg allele (LEPR
Gln223Arg + LEPR Arg223Arg genotypes) was not associ-
ated a significant risk of breast cancer in these women (OR
Table 1: Distribution of Leptin receptor (LEPR) alleles and genotypes in relation to breast cancer risk (unconditional logistic 
regression)
Cases Controls OR (95% CI) P-value OR (95% CI)* P-value
All women (n = 209) (n = 209)
Allele frequencies
LEPR (Gln) 0.49 0.51
LEPR (Arg) 0.51 0.49
Genotype frequencies
LEPR (Gln/Gln) 46 (22.0) 56 (26.8) 1.0
LEPR (Gln/Arg) 107 (51.2) 107 (51.2) 1.2 (0.8–2.0) 0.42 1.2 (0.8–2.0) 0.40
LEPR (Arg/Arg) 56 (26.8) 46 (22.0) 1.5 (0.8–2.6) 0.16 1.6 (0.9–3.2.8) 0.13
LEPR (Gln/Gln 46 (22.0) 56 (26.8) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 163 (78.0) 153 (73.2) 1.3 (0.8–2.0) 0.26 1.3 (0.8–2.1) 0.23
Pre-menopausal women (n = 114) (n = 121)
Allele frequencies
LEPR (Gln) 0.46 0.54
LEPR (Arg) 0.54 0.46
Genotype frequencies
LEPR (Gln/Gln) 23 (20.2) 38 (31.4) 1.00
LEPR (Gln/Arg) 60 (52.6) 54 (44.6) 1.8 (1.0–3.5) 0.06 1.8 (0.9–3.3) 0.07
LEPR (Arg/Arg) 31 (27.2) 29 (24.0) 1.8 (0.9–3.6) 0.12 1.8 (0.8–3.7) 0.14
LEPR (Gln/Gln 23 (20.2) 38 (31.4) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 91 (79.8) 83 (68.6) 1.8 (1.0–3.3) 0.05 1.8 (1.0–3.2) 0.07
Postmenopausal women (n = 95) (n = 88)
Allele frequencies
LEPR (Gln) 0.49 0.51
LEPR (Arg) 0.51 0.49
Genotype frequencies
LEPR (Gln/Gln) 23 (24.2) 18 (20.5) 1.00
LEPR (Gln/Arg) 47 (49.5) 53 (60.2) 0.7 (0.3–1.4) 0.33 0.7 (0.4–1.5) 0.42
LEPR (Arg/Arg) 25 (26.3) 17 (19.3) 1.2 (0.5–2.8) 0.75 1.2 (0.5–3.0) 0.62
LEPR (Gln/Gln 23 (24.2) 18 (20.5) 1.00
LEPR (Gln/Arg) + (Arg/Arg) 72 (75.8) 70 (79.5) 0.8 (0.4–1.6) 0.54 0.9 (0.4–1.8) 0.68
*Adjusted for age and waist/hip ratio (WHR)BMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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= 1.3, 95% CI 0.8–2.0, p = 0.26). Adjusting for waist/hip
ratio, a surrogate measure of obesity did not significantly
alter the risk profile in these women as shown in Table 1.
Premenopausal Women
Among premenopausal women, there was a marginally
increased risk of breast cancer with the LEPR 223Arg allele
(LEPR Gln223Arg + LEPR Arg223Arg): OR = 1.8, 95% CI
1.0–3.3, p = 0.05 (Table 1). The heterozygous LEPR
Gln223Arg genotype was associated with a modestly
increased risk of breast cancer (OR = 1.8, 95% CI 1.0–3.5,
p = 0.06). The homozygous LEPR Arg223Arg genotype
was also associated with some modest increase in breast
cancer risk (OR = 1.8, 95% CI 0.9–3.6, p = 0.12). These
risk profiles were unaltered when the analysis was
adjusted for waist/hip ratio and age (LEPR Gln223Arg +
LEPR Arg223Arg OR = 1.8, 95% CI 1–3.2, p = 0.07; LEPR
Gln223Arg genotype OR = 1.8, 95% CI 0.9–3.3, p = 0.07
and LEPR Arg223Arg genotype OR = 1.8, 95% CI 0.8–3.7,
p = 0.14).
Postmenopausal Women
Among postmenopausal women there was no significant
relationship between the LEPR Gln223Arg polymorphism
and breast cancer risk (Table 1). Adjusting for waist/hip
ratio did not significantly alter the risk profiles.
Discussion
The results of our study showed that the LEPR Gln223Arg
variant is highly polymorphic in the Nigerian population.
The LEPR 223Arg allele frequency of 0.49 in our study par-
ticipants is higher than figures reported in Caucasians
(0.45), Pima Indians (0.32), Arabs (0.34) but much lower
than figures in Asian populations (0.85) [28]. Although a
study of mixed U.S. population by Chung et al. [13]
reported little difference in LEPR 223Arg allele frequency
by racial groups, the study recruited only 26 blacks and
racial admixture in the U.S. population may partly
account for their finding. The International Hapmap
Project reported LEPR 223Arg allele frequencies of 0.61
among Yorubas in Ibadan, Nigeria and 0.53 in African
Americans. [29]
The evaluation of the relationship of the LEPR Gln223Arg
polymorphism and breast cancer risk showed that pre-
menopausal women carrying at least one LEPR 223Arg
allele were at a modestly increased risk of breast cancer
(OR = 1.8, 95% CI 1.0–3.3, p = 0.05); the risk was unal-
tered after adjusting for waist/hip ratio and age (OR = 1.8,
95% CI 1.0–3.2, p = 0.07). There was no association
between the LEPR Gln223Arg polymorphism and breast
cancer risk in postmenopausal women. Two studies
[22,23] evaluated the LEPR Gln223Arg polymorphism in
relation to breast cancer risk; one [22] in the Tunisia pop-
ulation reported significantly increased risk in both pre-
menopausal and postmenopausal women in a dose
dependent manner (OR = 1.68, 95% CI 1.12–2.50 and
OR = 2.26, 95% CI 1.31–3.90 for the LEPR Gln223Arg
and Arg223Arg genotypes, respectively). In addition, the
authors noted that the presence of the LEPR 223Arg allele
was associated with poorer overall survival. The second
study by Woo et al. [23] found no association between the
polymorphism and breast cancer risk in both premeno-
pausal and postmenopausal Korean women (OR = 0.54,
95% CI 0.19–1.81). The authors noted the rarity of the
LEPR 223Gln allele in the Korean population (allele fre-
quency, 0.09) and the small sample size of their study (45
breast cancer cases and 45 control subjects). Some inves-
tigators [16,18,21] have examined the relationship
between variants of the LEPR Gln223Arg polymorphism
and serum levels of leptin since there is some evidence
associating serum leptin levels with breast cancer risk
[17,18]. In a study involving 118 college students in
Greece (62 females and 56 males), Yiannkouris et al. [21]
reported significantly higher serum leptin levels in indi-
viduals who were homozygous LEPR  Arg223Arg com-
pared with those harboring at least one LEPR  223Gln
allele. Another study of 220 postmenopausal women in
the U.K. found significant association between serum lep-
tin levels and the LEPR genotype [16].
Although the actual mechanisms of leptin's role in breast
cancer risk are not completely known, several lines of evi-
dence provide support for leptin's broader physiological
role, including the regulation of several neuroendocrine
axes, some of which play a significant role in the patho-
genesis of breast cancer. Leptin treatment corrects the
hypogonadism of leptin-deficient ob/ob mice [30,31] and
starved normal mice [32], accelerates the onset of puberty
in rodents and increasing leptin levels may signal the
onset of puberty in boys and girls [33,34]. In addition,
leptin's pulsatile secretion is synchronized with the pulsa-
tility of luteinizing hormone and estradiol in normal
women [35]. Leptin has been shown to regulate GH secre-
tion [36] and serum leptin levels have been associated
with circulating IGF-1 and IGFBP-3 levels in normal and
GH-deficient humans [34,37]. In addition, circulating
leptin levels have been associated with certain life-style
factors, such as smoking and alcohol intake [34]. Interest-
ingly, the above endocrine axes and life-style factors have
also been implicated in the pathogenesis of breast cancer
via leptin's interaction with IGF-I and IGFBP-3 [38,39].
Tumor markers that are elevated in breast cancer can
upregulate leptin production. These factors, including
TNF-α, IL-1α, IL-1β, VEGF, and fibroblast growth factor 2
(FGF-2), raise leptin levels and promote tumor growth
and differentiation [40,41]. In experimental studies, lep-
tin consistently stimulated human breast epithelial cell
lines and breast cancer-derived cell lines resulting inBMC Cancer 2008, 8:338 http://www.biomedcentral.com/1471-2407/8/338
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increased DNA synthesis evaluated by thymidine incorpo-
ration test and increased cellular growth estimated by cel-
lular density [9-12]. Several down-stream effects of leptin
signaling leading to cellular proliferation were also
observed including increased expression of phosphor-
ylated signal transducers (STAT3), extracellular signal-reg-
ulated kinase (ERK), mitogen-activated protein kinases
(MAPK) and transcript activator protein (AP-1), and also
increased expression of cyclin dependent kinase-2 and
cyclin D1, two cell-cycle regulating proteins [9,10]. It has
been suggested that the single amino acid change in the
LEPR gene (LEPR Gln223Arg), a glutamine for an arginine
with a change from neutral to positive, could affect the
functionality of the receptor and alter its signaling capac-
ity [13,42,43]. The finding of higher leptin binding activ-
ity (LBA) levels in homozygous carriers of the G allele
(LEPR Arg223Arg) and higher levels of leptin in the LEPR
Arg223Arg homozygotes and our finding of increased pre-
menopausal breast cancer risk in women carrying the
LEPR 223Arg allele provides supportive evidence for this
proposition. It is possible that the leptin polymorphism is
in linkage disequilibrium with other genes that play a role
in breast cancer risk.
An important observation is the paucity of epidemiologi-
cal literature on the role of polymorphisms in the leptin
receptor (LEPR) gene in breast cancer susceptibility in
most populations and its complete absence in sub-Saha-
ran African populations. Much has been said about the
mechanisms of leptin-induced carcinogenesis in animal
models and correlation of serum leptin levels with breast
cancer risk [17-20]. The effect of genotypes such as LEPR
Gln223Arg polymorphism on breast cancer may vary
from one population to the other as a result of marked dif-
ferences in the distribution of the alleles in different pop-
ulations. The finding of interaction between LEPR
Gln223Arg genotypes and menopausal status and obesity
may also partly explain the differences in reports from var-
ious populations. In the developed countries with a much
higher percentage of postmenopausal breast cancer and a
higher proportion of obese women, LEPR Gln223Arg pol-
ymorphism may be expected to have more impact on risk
of the disease compared to the Nigerian population with
a lower prevalence of obesity. Some of the limitations of
this study include use of both incident and prevalent cases
of breast cancer. Given the report of poorer prognosis
associated with the LEPR 223Arg allele in some studies, it
is possible that some patients harboring this allele might
have died earlier leaving us with more patients with the
LEPR  223Gln allele. However, such a bias if prevent
would result in underestimation of the risk associated
with the putative high risk LEPR 223Arg allele. There is
currently no breast cancer screening program in Nigeria;
therefore patients with early pre-clinical disease may have
been missed in our study. Use of hospital controls is
necessitated by the limited research infrastructure such as
poor communication facilities and lack of population-
based cancer registries in developing countries such as
Nigeria.
Another issue of concern is the sample size of this study.
In fact, we estimate that with an allele frequency of .49 in
all women combined, a sample size of 139 cases and con-
trols provides a power of 80% to detect an odds ratio (OR)
of 2.0. There were a total of 209 cases and 209 controls in
our study population indicating that this sample size has
adequate statistical power to detect an OR of 2.0. How-
ever, when we stratify by menopausal status, the number
of cases and controls become much lower, thus decreasing
the statistical power of the study. For example, a sample
size of 137 premenopausal cases and 137 premenopausal
controls would be adequate to detect an odds ratio of 2.0
while there were 114 premenopausal cases and 121 pre-
menopausal controls in our study. It is possible that vari-
ations in LEPR polymorphisms and other low penetrance
genes may contribute to the marked worldwide variation
in breast cancer incidence, with the highest age-standard-
ized incidence rate (ASR) in North America (ASR, 99.4 per
100,000) and the lowest age-standardized incidence rates
in sub-Saharan Africa (ASR, 27.8 per 100,000 in West
Africa, 19.5 per 100,000 in East Africa and 16.5 per
100,000 in Central Africa) [44].
Conclusion
In conclusion, this study has demonstrated a modestly
increased risk of premenopausal breast cancer in women
harboring the LEPR 223Arg allele of the LEPR Gln223Arg
polymorphism of the leptin receptor gene. To the best of
our knowledge, ours is the first study to provide informa-
tion on the role of LEPR Gln223Arg polymorphism in
breast cancer risk in sub-Saharan African women, a popu-
lation characterized by paucity of epidemiological litera-
ture on the determinants of breast cancer and other
malignancies.
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